Semaglutide shows strong weight loss in adolescents but lacks long-term safety data on bone and growth

GLP-1 receptor agonists such as semaglutide yield significant weight loss in adolescents with obesity, achieving an average 16.1% BMI reduction in trials presented at the AAP 2026 conference. However, researchers warn that long-term safety data regarding bone density, lean mass, and neurodevelopment remain sparse. Because patients face weight regain upon stopping medication, medical experts emphasize structured transition planning to adult care.

GLP-1 trial results in adolescents

• ▪Gastrointestinal adverse events occurred in 62% of semaglutide participants in STEP TEENS and 64.8% of liraglutide participants in SCALE Teens.
• ▪A literature review presented at the American Academy of Pediatrics 2026 National Conference found that semaglutide reduced BMI by an average of 16.1% in adolescent trial participants.
• ▪In the STEP TEENS trial, 73% of adolescent participants taking semaglutide lost at least 5% of their BMI compared to 18% in the placebo group.
• ▪Adolescent participants in the SCALE Teens trial receiving liraglutide experienced a 0.22 drop in BMI Standard Deviation Score, with 43.3% losing at least 5% of their BMI.

Protecting bone and muscle health

• ▪A literature review presented at the AAP 2026 conference noted that pediatric GLP-1 trials rarely assess long-term outcomes for bone density, lean mass, or neurodevelopment.
• ▪Medical experts recommend that adolescent patients taking GLP-1 medications undergo nutritional counseling and strength training to preserve lean body mass and bone health.

Discontinuing GLP-1 therapy

• ▪In the SCALE Teens trial, participants who stopped taking liraglutide experienced an increase in BMI Standard Deviation Score that was not seen in those stopping placebo.
• ▪Weight regain typically occurs in adolescent patients after GLP-1 receptor agonist therapy is discontinued.

Adolescent GLP-1 literature review

• ▪Medical student Brett Conrad and co-authors wrote that care transitions for adolescents on GLP-1 medications must be planned before the final pediatric visit to avoid treatment interruption and weight regain.
• ▪Medical student Brett Conrad and co-authors reviewed 30 research sources published between January 2010 and February 2026 on GLP-1 medications in pediatric patients.

AAP pediatric health guidelines

• ▪The 2023 American Academy of Pediatrics Clinical Practice Guideline recommends offering weight-loss pharmacotherapy to adolescents aged 12 years or older as an adjunct to health behavior treatment.
• ▪The American Academy of Pediatrics recommends that pediatric patients reach a target of 60 minutes of moderate to vigorous physical activity each day.

Rising rates of US adolescent obesity

• ▪Rates of clinical obesity among U.S. adolescents from low-income households rose from 4.8% to 11.7%, while higher-income households saw no significant increase.
• ▪An analysis of NHANES data showed that U.S. adolescent clinical obesity, defined as excess adiposity with organ dysfunction, nearly doubled from 5.3% to 9.2% over two decades.
• ▪An analysis of NHANES data published in JAMA Pediatrics found that excess adiposity among U.S. adolescents aged 12 to 19 years increased from 14.2% in 1999-2000 to 18.2% in 2021-2023.

Classifying adolescent obesity and complications

• ▪Among U.S. adolescents with clinical obesity, isolated organ manifestations included respiratory dysfunction at 26.5%, metabolic cluster abnormalities at 23.6%, cardiovascular dysfunction at 18%, and hepatic impairment at 7.4%.
• ▪Preclinical obesity in adolescents involves excess adiposity without organ dysfunction and remained stable at approximately 9% in U.S. survey data.
• ▪Excess adiposity in adolescents is defined as a BMI-for-age at or above the 95th percentile accompanied by a waist-to-height ratio of at least 0.50.

Childhood obesity in Indonesia

• ▪In Indonesia, obesity affects 20 percent of the nation's 60 million school-age children, alongside persistent undernutrition.
• ▪Health experts report that Indonesia's childhood obesity rate has doubled over the past 10 years, though it is not yet widely recognized as a major health problem.

Debatable claims

• ▪Weight regain upon discontinuation makes GLP-1 therapy an unsustainable response to adolescent obesity
• ▪Immediate weight-loss benefits justify GLP-1 use in adolescents despite unknown developmental risks